Utilize este identificador para referenciar este registo: http://hdl.handle.net/10451/32304
Registo completo
Campo DCValorIdioma
degois.publication.firstPage54pt_PT
degois.publication.lastPage62pt_PT
degois.publication.titleCritical Reviews in Oncology/Hematologypt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematologypt_PT
dc.contributor.authorMarques, Rui Pedro-
dc.contributor.authorDuarte, Gonçalo S.-
dc.contributor.authorSterrantino, Carmelo-
dc.contributor.authorPais, Helena Luna-
dc.contributor.authorQuintela, António-
dc.contributor.authorMartins, Ana Paula-
dc.contributor.authorCosta, João-
dc.date.accessioned2018-03-13T15:35:18Z-
dc.date.available2018-03-13T15:35:18Z-
dc.date.issued2017-
dc.identifier.citationCritical Reviews in Oncology / Hematology 118 (2017) 54–62pt_PT
dc.identifier.issn1040-8428-
dc.identifier.urihttp://hdl.handle.net/10451/32304-
dc.description© 2017 Elsevier B.V. All rights reserved.pt_PT
dc.description.abstractUncertainty exists regarding the comparative effectiveness of triplet chemotherapy (FOLFOXIRI) as backbone first-line chemotherapy for metastatic colorectal cancer (mCRC). We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing triplet versus doublet chemotherapy (FOLFOX or FOLFIRI) as first-line therapy in mCRC. Methods and reporting followed PRISMA and SAMPL guidelines. Eight RCTs were included, comprising 1732 patients. In pooled analysis, FOLFOXIRI was associated with improvements in efficacy outcomes, notably with a 25% survival increase (95%CI: 10-37%). FOLFOXIRI was also associated with increased toxicity, with a non-significant 25% increase in the risk of patients experiencing grade ≥3 adverse events (95% CI: -3 to 61%) and with a 1.83 (95% CI: 1.62-2.07) increase in the rate ratio of grade ≥3 adverse events. Moderate quality evidence suggests that first-line FOLFOXIRI provides clinically meaningful efficacy benefits in this setting, at the expense of increased toxicity. Further research is warranted to better characterize safety and to evaluate the most beneficial combination with targeted agents.pt_PT
dc.language.isoengpt_PT
dc.publisherElsevierpt_PT
dc.rightsrestrictedAccesspt_PT
dc.subjectMetastatic colorectal cancerpt_PT
dc.subjectTriplet chemotherapypt_PT
dc.subjectFOLFOXIRIpt_PT
dc.subjectDoublet chemotherapypt_PT
dc.subjectFOLFOXpt_PT
dc.subjectFOLFIRIpt_PT
dc.titleTriplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer : a systematic review and meta-analysispt_PT
dc.typearticlept_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.peerreviewedyespt_PT
degois.publication.volume118pt_PT
dc.identifier.doi10.1016/j.critrevonc.2017.08.006pt_PT
Aparece nas colecções:IMM - Artigos em Revistas Internacionais
FM-CEMBE-Artigos em Revistas Internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Triplet_versus_doublet.pdf518,36 kBAdobe PDFVer/Abrir    Acesso Restrito. Solicitar cópia ao autor!


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.